Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Chin Med J (Engl). 2009 Sep 20;122(18):2123-8.
Macro- and microvascular diseases are the leading cause of morbidity and mortality in diabetic patients, but their mechanisms remain unclear. Recent reports provide evidence that the levels of CD55 and CD59 are decreased in diabetic microvascular diseases. However, very little is known about the levels of CD55 and CD59, the relationship between them and carotid artery intima-media thickness, and the effects of statins on CD55 and CD59 in diabetic macrovascular diseases.
The mean fluorescence intensity (MFI) of CD55 and CD59 expression on peripheral blood leucocyte subsets (lymphocytes, monocytes and neutrophils) was studied using flow cytometry, and carotid artery intima-media thickness was measured using B-mode ultrasonography in 23 healthy subjects (controls), 19 patients with type 2 diabetes (T2DM), and 43 patients with type 2 diabetes and macrovascular diseases (T2DM-M). The patients with T2DM-M were assigned to two subgroups based on whether statins were used: group with statins (n = 23) and group without statins (n = 20).
Compared with the controls and T2DM, the MFI of CD55 positive neutrophils was significantly lower in T2DM-M (P = 0.049 vs controls and P = 0.033 vs T2DM); similarly, the MFI of CD59 positive monocytes was also lower in T2DM-M (P = 0.038 vs controls and P = 0.043 vs T2DM). The MFI of CD59 positive neutrophils in T2DM-M was lower than in T2DM (P = 0.032). The levels of CD55 and CD59 were negatively associated with age and blood pressure (r = -0.245 - -0.352, P = 0.041 - 0.003), but not acute-phase reactants and carotid artery intima-media thickness. The levels of CD55 and CD59 increased after treatment with statins, but the results were not significantly different (P > 0.05).
CD55 and CD59 expressions on peripheral blood leucocytes are decreased in T2DM patients with macrovascular diseases. The results suggest that the decreased levels of complement regulatory proteins might play an important role in diabetic macrovascular diseases.
宏观和微观血管疾病是糖尿病患者发病率和死亡率的主要原因，但它们的发病机制尚不清楚。最近的报告提供了证据，表明糖尿病微血管疾病中 CD55 和 CD59 的水平降低。然而，关于 CD55 和 CD59 的水平、它们之间的关系以及他汀类药物对糖尿病大血管疾病中 CD55 和 CD59 的影响，人们知之甚少。
采用流式细胞术检测外周血白细胞亚群（淋巴细胞、单核细胞和中性粒细胞）上 CD55 和 CD59 表达的平均荧光强度（MFI），并用 B 型超声测量颈动脉内膜-中层厚度。23 名健康受试者（对照组）、19 名 2 型糖尿病患者（T2DM）和 43 名 2 型糖尿病合并大血管疾病患者（T2DM-M）参与了本研究。根据是否使用他汀类药物，将 T2DM-M 患者分为两组：他汀类药物组（n=23）和非他汀类药物组（n=20）。
与对照组和 T2DM 相比，T2DM-M 患者中性粒细胞 CD55 阳性的 MFI 显著降低（P=0.049 与对照组，P=0.033 与 T2DM）；同样，T2DM-M 患者单核细胞 CD59 阳性的 MFI 也较低（P=0.038 与对照组，P=0.043 与 T2DM）。T2DM-M 患者中性粒细胞 CD59 阳性的 MFI 低于 T2DM 患者（P=0.032）。CD55 和 CD59 的水平与年龄和血压呈负相关（r=-0.245 至-0.352，P=0.041 至 0.003），但与急性反应物质和颈动脉内膜-中层厚度无关。使用他汀类药物治疗后，CD55 和 CD59 的水平升高，但差异无统计学意义（P>0.05）。
患有大血管疾病的 2 型糖尿病患者外周血白细胞上的 CD55 和 CD59 表达减少。结果表明，补体调节蛋白水平的降低可能在糖尿病大血管疾病中发挥重要作用。
